Image For Activity Cover
Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI (JACC Cardiovascular Interventions January 2023)
Description

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) was firstly established in 2001.

Editors

JACC: Cardiovascular Interventions Editor-in-Chief
David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC/ECME Editor
Michael C. McDaniel, MD

Authors
Davide Capodanno, MD
Dominick J. Angiolillo, MD, PHD

Important Dates

Date of Release: January 9, 2023
Term of Approval/Date of CME/MOC/ECME Expiration: January 8, 2024

Summary
Availability: On-Demand
Expires on Jan 08, 2024
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By